California Attorney General Rob Bonta announced in a press conference that his office is filing a lawsuit against Eli Lilly (LLY), Novo Nordisk (NVO) and Sanofi (SNY) over insulin prices in the state. The suit also claims pharmacy benefit managers, or PBMs, CVS Caremark (CVS), Express Scripts (CI), and OptumRx (UNH) "have leveraged their market power to overcharge patients," according to Bonta. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
- Altimmune appoints Jordt as Chief Business Officer
- Eli Lilly price target raised to $400 from $395 at Barclays
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- ProQR Therapeutics shares remain ‘fairly valued,’ says JMP Securities